#CardioJC - Twitter Hashtag

over 2 years ago

@CardioNerdsJC STOP DAPT 2 - ACS failed to meet noninferiority. Problem with clopidogrel is the heterogeneity of response with 25% non responders. #cardiojc

0

3

0

95

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP,CACP @beaverspharmd

over 4 years ago

@CardioNerds and my peer faculty! It was an honor and a privilege being with you tonight! Thank you! #CardioJC

0

4

0

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP,CACP @beaverspharmd

over 4 years ago

My last comment @CardioNerds! I hope to see some of you all at @ACC #ACC22! #CardioJC

0

6

0

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP,CACP @beaverspharmd

over 4 years ago

@karanpdesai @seyi_dr @CardioNerdsJC I would say most people keep on at the time. It is discharge when the changes are made (unless other compelling reason). #CardioJC

0

6

1

0

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP,CACP @beaverspharmd

over 4 years ago

@CardioNerdsJC I think it depends on what you agree with/or accept in terms of limitations or the question you agree to accept. I do think it makes me feel like @ minimum they should be considered options in the ACS population post PCI (i.e. we may not need one to favor over another). #CardioJC

1

6

1

0

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP,CACP @beaverspharmd

over 4 years ago

@RaniKHasan @CardioNerds @RichardAFerraro This is an important point and as I stated at the start. When defining how critical this trial this is, I put it in this context about the strategies. #CardioJC

0

2

1

0

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP,CACP @beaverspharmd

over 4 years ago

@AlexBastiany @KateAltaWilcox @SVRaoMD Ha, I just said that too! You and I are typing at the same time. #CardioJC

1

2

0

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP,CACP @beaverspharmd

over 4 years ago

@CardioNerdsJC Love this question. As such in life need many different approaches to do this. We know clearly there are gaps in assuring women receive proper care or are considered to be at risk of have heart disease. We need to star there for sure! #CardioJC

1

5

0

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP,CACP @beaverspharmd

over 4 years ago

@CardioNerdsJC #CardioJC, I think this is a tough question and depends on the question being asked. For example, strategy versus agent (ticagrelor versus prasugel).

1

4

0

Karen Ho @KarenHo_Cares

almost 5 years ago

Come join @RichardWhitloc2 @dehghani_payam and Dr. Idris Bare in a discussion on the recent LAAOS III trial! #cardiojc #idrisneedstwitter

KarenHo_Cares's tweet photo. Come join @RichardWhitloc2 @dehghani_payam and Dr. Idris Bare in a discussion on the recent LAAOS III trial! #cardiojc #idrisneedstwitter https://t.co/YNteTr7xVL

0

4

0

CardioNerds Journal Club @CardioNerdsJC

about 5 years ago

Also, take a look at the adverse events #CardioJC

0

4

1

0

Seyi Bolorunduro MD MPH @seyi_dr

about 5 years ago

@AnkurKalraMD @Drroxmehran @KannuBansalMD @CardioNerdsJC I don’t know if we have a definite answer, the OCT sub study of COMPLETE trial showed that 39% of these non culprit obstructive lesions had TCFA , this is probably not the case in ISCHEMIA patients #CARDIOJC

1

2

0